Optimization of Treatment and Management of Schizophrenia in Europe

Summary

The purpose of the study is optimising current treatments in schizophrenia and explore novel therapeutic options for schizophrenia. The study intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new interventions. It is expected that the project will lead to evidence that is directly applicable to treatment guidelines, and will identify potential mechanisms for new drug development.

Conditions

• Schizophrenia
• Schizophreniform Disorder
• Schizoaffective Disorder

Interventions

DRUG

Amisulpride open label

4-week open label amisulpride treatment

DRUG

6-week amisulpride double blind treatment

6-week amisulpride double blind treatment

DRUG

6-week olanzapine double blind treatment

6-week olanzapine double blind treatment

DRUG

12-week clozapine open-label treatment

12-week clozapine open-label treatment

BEHAVIORAL

Psychosocial intervention

Psychosocial intervention

Sponsors & Collaborators

• King's College London

  collaborator OTHER

• Technical University of Munich

  collaborator OTHER

• University of Manchester

  collaborator OTHER

• Ludwig-Maximilians - University of Munich

  collaborator OTHER

• Rene Kahn

  lead OTHER

Principal Investigators

• René Kahn, MD, PhD · University Medical Center Utrecht, the Netherlands

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

40 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2011-05-31

Primary Completion

2016-04-30

Completion

2016-04-30

Countries

• Australia
• Austria
• Belgium
• Bulgaria
• Czechia
• Denmark
• France
• Germany
• Israel
• Italy
• Netherlands
• Poland
• Romania
• Spain
• Switzerland
• United Kingdom

Study Locations